All Stories

Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists

Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial.

Jun 5, 2025 - 16:15
 0
Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists
Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial.
Read More

Tags:

Previous Article

Schott Pharma throws down €100M to build new sterile cartridge facility at Hunga...

Next Article

Fierce Biotech Layoff Tracker 2025: Rapt reduces workforce; Plexium pares down s...

Related Posts

Fierce Biotech Fundraising Tracker '25: Allay accesses $57M series D; SpyGlass secures $75M series D

Fierce Biotech Fundraising Tracker '25: Allay accesses ...

Jun 5, 2025  0

Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt

Sanofi, Regeneron's IL-33 drug fails one of 2 COPD stud...

May 30, 2025  0

Fierce Biotech Layoff Tracker 2025: Leap halves team; Atara lays off 30% of staffers

Fierce Biotech Layoff Tracker 2025: Leap halves team; A...

May 13, 2025  0